<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEDROXYPROGESTERONE ACETATE - medroxyprogesterone acetate injection, suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Medroxyprogesterone Acetate Injectable Suspension, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>Physician Information</h1>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Women who use Medroxyprogesterone Acetate Injectable Suspension, USP may lose significant bone mineral density.  Bone loss is greater with increasing duration of use and may not be completely reversible.</span></p>
<p><span class="Bold">It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and increase the risk for <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fracture</span> in later life.</span></p>
<p><span class="Bold">Medroxyprogesterone Acetate Injectable Suspension, USP should be used as a long-term birth control method (e.g. longer than 2 years) only if other birth control methods are inadequate. (See <a href="#Warnings">WARNINGS</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP contains medroxyprogesterone acetate, a derivative of progesterone, as its active ingredient. Medroxyprogesterone Acetate is active by the parenteral and oral routes of administration. It is a white to off-white; odorless crystalline powder that is stable in air and that melts between 200°C and 210°C. It is freely soluble in chloroform, soluble in acetone and dioxane, sparingly soluble in alcohol and methanol, slightly soluble in ether, and insoluble in water.</p>
<p>The chemical name for Medroxyprogesterone Acetate is pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6α-).</p>
<p>The structural formula is as follows:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cd0bbdb2-754e-4e66-8f36-985b5819d642&amp;name=medroxyprogesterone-01.jpg"><p class="MultiMediaCaption">medroxyprogesterone acetate</p>
</div>
<p>Medroxyprogesterone Acetate Injectable Suspension, USP for intramuscular (IM) injection is available in vials and prefilled syringes, each containing 1 mL of Medroxyprogesterone Acetate sterile aqueous suspension 150 mg/mL.<br>Each mL contains:</p>
<a name="i0438b144-55e6-4e64-8429-814e28b84166"></a><table width="60%">
<col align="left" width="60%">
<col align="right" width="40%">
<tbody class="Headless">
<tr class="First">
<td align="left">Medroxyprogesterone acetate</td>
<td align="right">150 mg</td>
</tr>
<tr>
<td align="left">Polyethylene glycol 3350</td>
<td align="right">28.9 mg</td>
</tr>
<tr>
<td align="left">Polysorbate 80</td>
<td align="right">2.41 mg</td>
</tr>
<tr>
<td align="left">Sodium chloride</td>
<td align="right">8.68 mg</td>
</tr>
<tr>
<td align="left">Methylparaben</td>
<td align="right">1.37 mg</td>
</tr>
<tr>
<td align="left">Propylparaben</td>
<td align="right">0.150 mg</td>
</tr>
<tr class="Last">
<td align="left">Water for injection</td>
<td align="right">          qs</td>
</tr>
</tbody>
</table>
<p>When necessary, pH is adjusted with sodium hydroxide or hydrochloric acid, or both.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP, when administered at the recommended dose to women every 3 months, inhibits the secretion of gonadotropins which, in turn, prevents follicular maturation and ovulation and results in endometrial thinning. These actions produce its contraceptive effect.</p>
<p>Following a single 150 mg IM dose of Medroxyprogesterone Acetate Injectable Suspension, USP, Medroxyprogesterone Acetate concentrations, measured by an extracted radioimmunoassay procedure, increase for approximately 3 weeks to reach peak plasma concentrations of 1 to 7 ng/mL. The levels then decrease exponentially until they become undetectable (&lt;100 pg/mL) between 120 to 200 days following injection. Using an unextracted radioimmunoassay procedure for the assay of Medroxyprogesterone Acetate in serum, the apparent half-life for Medroxyprogesterone Acetate following IM administration of Medroxyprogesterone Acetate Injectable Suspension, USP is approximately 50 days. </p>
<p>Women with lower body weights conceive sooner than women with higher body weights after discontinuing Medroxyprogesterone Acetate Injectable Suspension, USP.</p>
<p>The effect of hepatic and/or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the pharmacokinetics of Medroxyprogesterone Acetate Injectable Suspension, USP is unknown.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone Acetate Injectable Suspension, USP long-term (see <a href="#Warnings">WARNINGS</a>.)  It is a long-term injectable contraceptive in women when administered at 3-month (13-week) intervals. Dosage does not need to be adjusted for body weight.</p>
<p>In five clinical studies using Medroxyprogesterone Acetate Injectable Suspension, USP, the 12-month failure rate for the group of women treated with Medroxyprogesterone Acetate Injectable Suspension, USP was zero (no pregnancies reported) to 0.7 by Life-Table method. Pregnancy rates with contraceptive measures are typically reported for only the first year of use as shown in Table 1. Except for intrauterine devices (IUD), implants, sterilization, and Medroxyprogesterone Acetate Injectable Suspension, USP, the efficacy of these contraceptive measures depends in part on the reliability of use. The effectiveness of Medroxyprogesterone Acetate Injectable Suspension, USP is dependent on the patient returning every 3 months (13 weeks) for reinjection.</p>
<a name="i153c715e-7993-4539-88d3-ed5ae4804c53"></a><table width="80%">
<caption><span>Table 1 Lowest Expected and Typical Failure Rates<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Expressed as Percent of Women Experiencing an Accidental Pregnancy in the First Year of Continuous Use</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead><tr class="First Last">
<th align="left">Method</th>
<th align="center">Lowest Expected</th>
<th align="center">Typical</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left">
<span class="Italics">Source:</span> Trussell et al<span class="Sup">1</span>
</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Lowest expected - when used exactly as directed. <br>Typical - includes those not following directions exactly. </dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>from Norplant<span class="Sup">®</span> package insert.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Injectable progestogen</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Medroxyprogesterone</td>
<td align="center">0.3</td>
<td align="center">0.3</td>
</tr>
<tr>
<td align="left">  Acetate</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="left">Implants</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left">  Norplant (6 capsules)</td>
<td align="center">0.2<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td align="center">0.2<a href="#footnote-2" class="Sup">†</a>
</td>
</tr>
<tr>
<td class="Toprule" align="left">Female sterilization</td>
<td class="Toprule" align="center">0.2</td>
<td class="Toprule" align="center">0.4</td>
</tr>
<tr>
<td class="Toprule" align="left">Male sterilization</td>
<td class="Toprule" align="center">0.1</td>
<td class="Toprule" align="center">0.15</td>
</tr>
<tr>
<td class="Toprule" align="left">Pill</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">3</td>
</tr>
<tr>
<td align="left">  Combined</td>
<td align="center">0.1</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Progestogen only</td>
<td align="center">0.5</td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="left">IUD</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center">3</td>
</tr>
<tr>
<td align="left">  Progestasert</td>
<td align="center">2</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Copper T 380A</td>
<td align="center">0.8</td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule" align="left">Condom</td>
<td class="Toprule" align="center">2</td>
<td class="Toprule" align="center">12</td>
</tr>
<tr>
<td class="Toprule" align="left">Diaphragm</td>
<td class="Toprule" align="center">6</td>
<td class="Toprule" align="center">18</td>
</tr>
<tr>
<td class="Toprule" align="left">Cap</td>
<td class="Toprule" align="center">6</td>
<td class="Toprule" align="center">18</td>
</tr>
<tr>
<td class="Toprule" align="left">Spermicides</td>
<td class="Toprule" align="center">3</td>
<td class="Toprule" align="center">21</td>
</tr>
<tr>
<td class="Toprule" align="left">Sponge</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left">  Parous women</td>
<td align="center">9</td>
<td align="center">28</td>
</tr>
<tr>
<td align="left">  Nulliparous women</td>
<td align="center">6</td>
<td align="center">18</td>
</tr>
<tr>
<td class="Toprule" align="left">Periodic abstinence</td>
<td class="Toprule" align="center">1–9</td>
<td class="Toprule" align="center">20</td>
</tr>
<tr>
<td class="Toprule" align="left">Withdrawal</td>
<td class="Toprule" align="center">4</td>
<td class="Toprule" align="center">18</td>
</tr>
<tr class="Last">
<td class="Toprule" align="left">No method</td>
<td class="Toprule" align="center">85</td>
<td class="Toprule" align="center">85</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li>Known or suspected pregnancy or as a diagnostic test for pregnancy.</li>
<li>Undiagnosed <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</li>
<li>Known or suspected malignancy of breast.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, or current or past history of thromboembolic disorders, or cerebral vascular disease.</li>
<li>Significant liver disease.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Medroxyprogesterone Acetate Injectable Suspension, USP (Medroxyprogesterone Acetate or any of its other ingredients).</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>1. Loss of Bone Mineral Density</h2>
<p class="First"><span class="Bold">Use of Medroxyprogesterone Acetate Injectable Suspension, USP reduces serum estrogen levels and is associated with significant loss of bone mineral density (BMD) as bone metabolism accommodates to a lower estrogen level.  This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion.  It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP by younger women will reduce peak bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and increase the risk for <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fracture</span> in later life.  In both adults and adolescents, the decrease in BMD appears to be at least partially reversible after Medroxyprogesterone Acetate Injectable Suspension, USP is discontinued and ovarian estrogen production increases.  A study to assess the reversibility of loss of BMD in adolescents is ongoing.</span></p>
<p><span class="Bold">Medroxyprogesterone Acetate Injectable Suspension, USP should be used as a long-term birth control method (e.g. longer than 2 years) only if other birth control methods are inadequate.  BMD should be evaluated when a woman needs to continue to use Medroxyprogesterone Acetate Injectable Suspension, USP long term.     In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity.</span></p>
<p><span class="Bold">Other birth control methods should be considered in the risk/benefit analysis for the use of Medroxyprogesterone Acetate Injectable Suspension, USP in women with <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> risk factors.  Medroxyprogesterone Acetate Injectable Suspension, USP can pose an additional risk in patients with risk factors for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, <span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span>, strong family history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> or chronic use of drugs that can reduce bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> such as anticonvulsants or corticosteroids).  Although there are no studies addressing whether calcium and Vitamin D may lessen BMD loss in women using Medroxyprogesterone Acetate Injectable Suspension, USP, all patients should have adequate calcium and Vitamin D intake.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>BMD Changes in Adult Women</h3>
<p class="First"><span class="Bold">In a controlled, clinical study, adult women using Medroxyprogesterone Acetate Injectable Suspension, USP for up to 5 years showed spine and hip BMD mean decreases of 5–6%, compared to no significant change in BMD in the control group.  The decline in BMD was more pronounced during the first two years of use, with smaller declines in subsequent years.  Mean changes in lumbar spine BMD of -2.86%, -4.11%, -4.89%, -4.93% and -5.38% after 1, 2, 3, 4, and 5 years, respectively, were observed.  Mean decreases in BMD of the total hip and femoral neck were similar.</span></p>
<p><span class="Bold">After stopping use of Medroxyprogesterone Acetate Injectable Suspension, USP (150 mg), there was partial recovery of BMD toward baseline values during the 2-year post-therapy period.  Longer duration of treatment was associated with less complete recovery during this 2-year period following the last injection.  Table 2 shows the extent of recovery of BMD for women who completed 5 years of treatment.</span></p>
<a name="i62d96f79-c576-4f03-86d5-e1f4c2b35351"></a><table width="90%">
<caption><span>Table 2.  Mean Percent Change from Baseline in BMD in Adults by Skeletal Site and Cohort</span></caption>
<col align="left" width="16%">
<col align="left" width="14%">
<col align="left" width="14%">
<col align="left" width="14%">
<col align="left" width="14%">
<col align="left" width="14%">
<col align="left" width="14%">
<thead>
<tr class="First">
<th class="Lrule" align="center" rowspan="2" valign="top">Time in<br> Study</th>
<th class="Lrule" align="center" colspan="2">Spine</th>
<th class="Lrule" align="center" colspan="2">Total Hip</th>
<th class="Lrule Rrule" align="center" colspan="2">Femoral Neck</th>
</tr>
<tr class="Last">
<th class="Lrule Toprule" align="left">Medroxy-progesterone Acetate<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Lrule Toprule" align="left" valign="top">Control<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</th>
<th class="Lrule Toprule" align="left">Medroxy-progesterone Acetate<a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Lrule Toprule" align="left" valign="top">Control<a href="#footnote-4" class="Sup">†</a>
</th>
<th class="Lrule Toprule" align="left">Medroxy-progesterone Acetate<a href="#footnote-3" class="Sup">*</a>
</th>
<th class="Lrule Rrule Toprule" align="left" valign="top">Control<a href="#footnote-4" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>The treatment group consisted of women who received Medroxyprogesterone Acetate Injectable Suspension, USP for 5 years and were then followed for 2 years post-use.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>The control group consisted of women who did not use hormonal contraception and were followed for 7 years.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">5 years</span></td>
<td class="Lrule" align="left"><span class="Bold">n=33</span></td>
<td class="Lrule" align="left"><span class="Bold">n=105</span></td>
<td class="Lrule" align="left"><span class="Bold">n=21</span></td>
<td class="Lrule" align="left"><span class="Bold">n=65</span></td>
<td class="Lrule" align="left"><span class="Bold">n=34</span></td>
<td class="Lrule Rrule" align="left"><span class="Bold">n=106</span></td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"><span class="Bold">-5.38%</span></td>
<td class="Lrule" align="left"><span class="Bold">0.43%</span></td>
<td class="Lrule" align="left"><span class="Bold">-5.16%</span></td>
<td class="Lrule" align="left"><span class="Bold">0.19%</span></td>
<td class="Lrule" align="left"><span class="Bold">-6.12%</span></td>
<td class="Lrule Rrule" align="left"><span class="Bold">-0.27%</span></td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="Bold">7 years</span></td>
<td class="Lrule Toprule" align="left"><span class="Bold">n=12</span></td>
<td class="Lrule Toprule" align="left"><span class="Bold">n=60</span></td>
<td class="Lrule Toprule" align="left"><span class="Bold">n=7</span></td>
<td class="Lrule Toprule" align="left"><span class="Bold">n=39</span></td>
<td class="Lrule Toprule" align="left"><span class="Bold">n=13</span></td>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">n=63</span></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"></td>
<td class="Lrule" align="left"><span class="Bold">-3.13%</span></td>
<td class="Lrule" align="left"><span class="Bold">0.53%</span></td>
<td class="Lrule" align="left"><span class="Bold">-1.34%</span></td>
<td class="Lrule" align="left"><span class="Bold">0.94%</span></td>
<td class="Lrule" align="left"><span class="Bold">-5.38%</span></td>
<td class="Lrule Rrule" align="left"><span class="Bold">-0.11%</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>BMD Changes in Adolescent Females (12–18 years of age)</h3>
<p class="First"><span class="Bold">Preliminary results from an ongoing, open-label, self-selected, non-randomized clinical study of adolescent females (12–18 years) also showed that Medroxyprogesterone Acetate Injectable Suspension, USP use was associated with a significant decline in BMD from baseline (Table 3).  In general, adolescents increase bone density during the period of growth following <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>, as seen in the untreated cohort.  However, the two cohorts were not matched at baseline for age, gynecologic age, race, BMD and other factors that influence the rate of acquisition of bone mineral density, with the result that they differed with respect to these demographic factors.</span></p>
<p><span class="Bold">Preliminary data from the small number of adolescents participating in the 2-year post-use observation period demonstrated partial recovery of BMD.</span></p>
<a name="i609519ba-89f8-4801-84e8-73f26228b114"></a><table width="80%">
<caption><span>Table 3.  Mean Percent Change from Baseline in BMD in Adolescents by Skeletal Site and Cohort</span></caption>
<col align="left" width="30%">
<col align="center" width="14%">
<col align="center" width="21%">
<col align="center" width="14%">
<col align="center" width="21%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" valign="top">Duration of Treatment</th>
<th class="Lrule" align="center" colspan="2">Medroxyprogesterone<br> Acetate Injectable<br> Suspension, USP<br>(150 mg IM)</th>
<th class="Lrule Rrule" align="center" colspan="2" valign="top">Unmatched, Untreated <br>Cohort</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Toprule" align="center">N</th>
<th class="Lrule Toprule" align="center">Mean % Change</th>
<th class="Lrule Toprule" align="center">N</th>
<th class="Lrule Rrule Toprule" align="center">Mean % Change</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">Total Hip BMD</span></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 60 (1.2 years)</td>
<td class="Lrule" align="center">103</td>
<td class="Lrule" align="center">-2.82</td>
<td class="Lrule" align="center">171</td>
<td class="Lrule Rrule" align="center">1.32</td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 144 (2.8 years)</td>
<td class="Lrule" align="center">45</td>
<td class="Lrule" align="center">-6.16</td>
<td class="Lrule" align="center">111</td>
<td class="Lrule Rrule" align="center">1.74</td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 240 (4.6 years)</td>
<td class="Lrule" align="center">9</td>
<td class="Lrule" align="center">-6.92</td>
<td class="Lrule" align="center">69</td>
<td class="Lrule Rrule" align="center">1.12</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="Bold">Femoral Neck BMD</span></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 60</td>
<td class="Lrule" align="center">103</td>
<td class="Lrule" align="center">-3.05</td>
<td class="Lrule" align="center">171</td>
<td class="Lrule Rrule" align="center">1.87</td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 144 </td>
<td class="Lrule" align="center">45</td>
<td class="Lrule" align="center">-6.01</td>
<td class="Lrule" align="center">111</td>
<td class="Lrule Rrule" align="center">2.54</td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 240</td>
<td class="Lrule" align="center">9</td>
<td class="Lrule" align="center">-6.06</td>
<td class="Lrule" align="center">69</td>
<td class="Lrule Rrule" align="center">1.45</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="Bold">Lumbar Spine BMD</span></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 60</td>
<td class="Lrule" align="center">104</td>
<td class="Lrule" align="center">-2.42</td>
<td class="Lrule" align="center">171</td>
<td class="Lrule Rrule" align="center">3.47</td>
</tr>
<tr>
<td class="Lrule" align="left">  Week 144</td>
<td class="Lrule" align="center">46</td>
<td class="Lrule" align="center">-2.78</td>
<td class="Lrule" align="center">111</td>
<td class="Lrule Rrule" align="center">5.41</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Week 240</td>
<td class="Lrule" align="center">9</td>
<td class="Lrule" align="center">-4.17</td>
<td class="Lrule" align="center">70</td>
<td class="Lrule Rrule" align="center">5.12</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>2. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities</h2>
<p class="First">Most women using Medroxyprogesterone Acetate Injectable Suspension, USP experience disruption of menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns. Altered menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns include irregular or unpredictable <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, or rarely, heavy or continuous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> persists or is severe, appropriate investigation should be instituted to rule out the possibility of organic pathology, and appropriate treatment should be instituted when necessary.</p>
<p>As women continue using Medroxyprogesterone Acetate Injectable Suspension, USP, fewer experience irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and more experience <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. By month 12 <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> was reported by 55% of women, and by month 24 <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> was reported by 68% of women using Medroxyprogesterone Acetate Injectable Suspension, USP.<span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>3. Cancer Risks</h2>
<p class="First">Long-term case-controlled surveillance of users of Medroxyprogesterone Acetate Injectable Suspension, USP found slight or no increased overall risk of breast cancer<span class="Sup">3</span> and no overall increased risk of ovarian,<span class="Sup">4</span> liver,<span class="Sup">5</span> or cervical<span class="Sup">6</span> cancer and a prolonged, protective effect of reducing the risk of endometrial<span class="Sup">7</span> cancer in the population of users.</p>
<p>A pooled analysis<span class="Sup">14</span> from two case-control studies, the World Health Organization Study<span class="Sup">3</span> and the New Zealand Study<span class="Sup">13</span>, reported the relative risk (RR) of breast cancer for women who had ever used Medroxyprogesterone Acetate Injectable Suspension, USP as 1.1 (95% confidence interval (CI) 0.97 to 1.4). Overall, there was no increase in risk with increasing duration of use of Medroxyprogesterone Acetate Injectable Suspension, USP. The RR of breast cancer for women of all ages who had initiated use of Medroxyprogesterone Acetate Injectable Suspension, USP within the previous 5 years was estimated to be 2.0 (95% CI 1.5 to 2.8).</p>
<p>The World Health Organization Study<span class="Sup">3,</span> a component of the pooled analysis<span class="Sup">14</span> described above, showed an increased RR of 2.19 (95% CI 1.23 to 3.89) of breast cancer associated with use of Medroxyprogesterone Acetate Injectable Suspension, USP in women whose first exposure to drug was within the previous 4 years and who were under 35 years of age. However, the overall RR for ever-users of Medroxyprogesterone Acetate Injectable Suspension, USP was only 1.2 (95% CI 0.96 to 1.52).</p>
<p>[<span class="Bold">NOTE:</span> A RR of 1.0 indicates neither an increased nor a decreased risk of cancer associated with the use of the drug, relative to no use of the drug. In the case of the subpopulation with a RR of 2.19, the 95% CI is fairly wide and does not include the value of 1.0, thus inferring an increased risk of breast cancer in the defined subgroup relative to nonusers. The value of 2.19 means that women whose first exposure to drug was within the previous 4 years and who are under 35 years of age have a 2.19 fold (95% CI 1.23 to 3.89-fold) increased risk of breast cancer relative to nonusers. The National Cancer Institute<span class="Sup">8</span> reports an average annual incidence rate for breast cancer for US women, all races, age 30 to 34 years of 26.7 per 100,000. A RR of 2.19, thus, increases the possible risk from 26.7 to 58.5 cases per 100,000 women. The attributable risk, thus, is 31.8 per 100,000 women per year.]</p>
<p>A statistically insignificant increase in RR estimates of invasive squamous-cell cervical cancer has been associated with the use of Medroxyprogesterone Acetate Injectable Suspension, USP in women who were first exposed before the age of 35 years (RR 1.22 to 1.28 and 95% CI 0.93 to 1.70). The overall, nonsignificant relative rate of invasive squamous-cell cervical cancer in women who ever used Medroxyprogesterone Acetate Injectable Suspension, USP was estimated to be 1.11 (95% CI 0.96 to 1.29). No trends in risk with duration of use or times since initial or most recent exposure were observed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>4. Thromboembolic Disorders</h2>
<p class="First">The physician should be alert to the earliest manifestations of thrombotic disorders (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorders</span>, and retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>). Should any of these occur or be suspected, the drug should not be readministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>5. Ocular Disorders</h2>
<p class="First">Medication should not be readministered pending examination if there is a sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> or if there is a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, medication should not be readministered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>6. Unexpected Pregnancies</h2>
<p class="First">To ensure that Medroxyprogesterone Acetate Injectable Suspension, USP is not administered inadvertently to a pregnant woman, the first injection must be given <span class="Bold">ONLY</span> during the first 5 days of a normal menstrual period; <span class="Bold">ONLY</span> within the first 5-days postpartum if not breast-feeding, and if exclusively breast-feeding, <span class="Bold">ONLY</span> at the sixth postpartum week (see <a href="#Dosage_Administration">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Neonates from unexpected pregnancies that occur 1 to 2 months after injection of Medroxyprogesterone Acetate Injectable Suspension, USP may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The attributable risk is low because such pregnancies are uncommon.<span class="Sup">9,10</span></p>
<p>A significant increase in incidence of <span class="product-label-link" type="condition" conceptid="79126" conceptname="Polysyndactyly">polysyndactyly</span> and <span class="product-label-link" type="condition" conceptid="434153" conceptname="Congenital chromosomal disease">chromosomal anomalies</span> was observed among infants of users of Medroxyprogesterone Acetate Injectable Suspension, USP, the former being most pronounced in women under 30 years of age. The unrelated nature of these defects, the lack of confirmation from other studies, the distant preconceptual exposure to Medroxyprogesterone Acetate Injectable Suspension, USP, and the chance effects due to multiple statistical comparisons, make a causal association unlikely.<span class="Sup">11</span></p>
<p>Neonates exposed to Medroxyprogesterone Acetate <span class="Italics">in utero</span> and followed to adolescence, showed no evidence of any adverse effects on their health including their physical, intellectual, sexual, or social development.</p>
<p>Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in male and female fetuses. The risk of <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span> (five to eight per 1,000 male births in the general population) may be approximately doubled with exposure to these drugs. There are insufficient data to quantify the risk to exposed female fetuses, but because some of these drugs induce mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus and because of the increased association of <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span> in the male fetus, it is prudent to avoid the use of these drugs during the first trimester of pregnancy.</p>
<p>To ensure that Medroxyprogesterone Acetate Injectable Suspension, USP is not administered inadvertently to a pregnant woman, it is important that the first injection be given only during the first 5 days after the onset of a normal menstrual period within 5 days postpartum if not breast-feeding and if breast-feeding, at the sixth week postpartum (see <a href="#Dosage_Administration">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>7. <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></h2>
<p class="First">Health-care providers should be alert to the possibility of an <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> among women using Medroxyprogesterone Acetate Injectable Suspension, USP who become pregnant or complain of severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>8. Lactation</h2>
<p class="First">Detectable amounts of drug have been identified in the milk of mothers receiving Medroxyprogesterone Acetate Injectable Suspension, USP. In nursing mothers treated with Medroxyprogesterone Acetate Injectable Suspension, USP, milk composition, quality, and amount are not adversely affected. Neonates and infants exposed to medroxyprogesterone from breast milk have been studied for developmental and behavioral effects through puberty. No adverse effects have been noted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9"></a><p></p>
<h2>9. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reaction</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> have been reported with the use of Medroxyprogesterone Acetate Injectable Suspension, USP. If an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs appropriate therapy should be instituted. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require emergency medical treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>GENERAL</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>1. Physical Examination</h3>
<p class="First">It is good medical practice for all women to have annual history and physical examinations, including women using Medroxyprogesterone Acetate Injectable Suspension, USP. The physical examination, however, may be deferred until after initiation of Medroxyprogesterone Acetate Injectable Suspension, USP if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span> and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<h3>2. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h3>
<p class="First">Because progestational drugs may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, conditions that might be influenced by this condition, such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and cardiac or renal dysfunction, require careful observation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<h3>3. Weight Changes</h3>
<p class="First">There is a tendency for women to gain weight while on therapy with Medroxyprogesterone Acetate Injectable Suspension, USP. From an initial average body weight of 136 lb, women who completed 1 year of therapy with Medroxyprogesterone Acetate Injectable Suspension, USP gained an average of 5.4 lb. Women who completed 2 years of therapy gained an average of 8.1 lb.</p>
<p>Women who completed 4 years gained an average of 13.8 lb. Women who completed 6 years gained an average of 16.5 lb. Two percent of women withdrew from a large-scale clinical trial because of excessive <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.4"></a><p></p>
<h3>4. Return of Fertility</h3>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP has a prolonged contraceptive effect. In a large US study of women who discontinued use of Medroxyprogesterone Acetate Injectable Suspension, USP to become pregnant, data are available for 61% of them. Based on Life-Table analysis of these data, it is expected that 68% of women who do become pregnant may conceive within 12 months, 83% may conceive within 15 months, and 93% may conceive within 18 months from the last injection. The median time to conception for those who do conceive is 10 months following the last injection with a range of 4 to 31 months, and is unrelated to the duration of use. No data are available for 39% of the patients who discontinued Medroxyprogesterone Acetate Injectable Suspension, USP to become pregnant and who were lost to follow-up or changed their mind. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.5"></a><p></p>
<h3>5. CNS Disorders and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> </h3>
<p class="First">Patients who have a history of psychic <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug not be readministered if the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs.</p>
<p>There have been a few reported cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients who were treated with Medroxyprogesterone Acetate Injectable Suspension, USP. Association with drug use or pre-existing conditions is not clear.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.6"></a><p></p>
<h3>6. Carbohydrate Metabolism</h3>
<p class="First">A decrease in glucose tolerance has been observed in some patients on Medroxyprogesterone Acetate Injectable Suspension, USP treatment. The mechanism of this decrease is obscure. For this reason, diabetic patients should be carefully observed while receiving such therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.7"></a><p></p>
<h3>7. Liver Function</h3>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops, consideration should be given to not readministering the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.8"></a><p></p>
<h3>8. Protection Against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span></h3>
<p class="First">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.2"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">Aminoglutethimide administered concomitantly with the Medroxyprogesterone Acetate Injectable Suspension, USP may significantly depress the serum concentrations of medroxyprogesterone acetate.<span class="Sup">12</span> Users of Medroxyprogesterone Acetate Injectable Suspension, USP should be warned of the possibility of decreased efficacy with the use of this or any related drugs.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.3"></a><p></p>
<h2>LABORATORY TEST INTERACTIONS</h2>
<p class="First">The pathologist should be advised of progestin therapy when relevant specimens are submitted.</p>
<p>The following laboratory tests may be affected by progestins including Medroxyprogesterone Acetate Injectable Suspension, USP:</p>
<dl>
<dt>(a)</dt>
<dd>Plasma and urinary steroid levels are decreased (eg, progesterone, estradiol, pregnanediol, testosterone, cortisol). </dd>
<dt>(b)</dt>
<dd>Gonadotropin levels are decreased.</dd>
<dt>(c)</dt>
<dd>Sex-hormone-binding-globulin concentrations are decreased. </dd>
<dt>(d)</dt>
<dd>Protein-bound iodine and butanol extractable protein-bound iodine may increase.<br>T<span class="Sub">3</span>-uptake values may decrease.</dd>
<dt>(e)</dt>
<dd>Coagulation test values for <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> (Factor II), and Factors VII, VIII, IX, and X may increase.</dd>
<dt>(f)</dt>
<dd>Sulfobromophthalein and other liver function test values may be increased.</dd>
<dt>(g)</dt>
<dd>The effects of Medroxyprogesterone Acetate on lipid metabolism are inconsistent. Both increases and decreases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and high-density lipoprotein (HDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> have been observed in studies.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.4"></a><p></p>
<h2>CARCINOGENESIS</h2>
<p class="First">See "<a href="#Warnings">WARNINGS</a>" section 3.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.5"></a><p></p>
<h2>PREGNANCY</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<h3>Pregnancy Category X</h3>
<p class="First">See "<a href="#Warnings">WARNINGS</a>" section 6.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">See "<a href="#Warnings">WARNINGS</a>" section 8.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP is not indicated before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span>.  Use of Medroxyprogesterone Acetate Injectable Suspension, USP is associated with significant loss of BMD.  This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion.  <span class="Bold">In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity. </span> It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP by younger women will reduce peak bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and increase the risk of <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span> in later life.  Other than concerns about loss of BMD, the safety and effectiveness are expected to be the same for postmenarchal adolescents and adult women.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.8"></a><p></p>
<h2>INFORMATION FOR THE PATIENT</h2>
<p class="First">See <a href="#Patient_Labeling">Patient Labeling</a>.</p>
<p>Patient labeling is included with each single-dose vial and prefilled syringe of Medroxyprogesterone Acetate Injectable Suspension, USP to help describe its characteristics to the patient. It is recommended that prospective users be given this labeling and be informed about the risks and benefits associated with the use of Medroxyprogesterone Acetate Injectable Suspension, USP, as compared with other forms of contraception or with no contraception at all. It is recommended that physicians or other health-care providers responsible for those patients advise them at the beginning of treatment that their menstrual cycle may be disrupted and that irregular and unpredictable <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting results, and that this usually decreases to the point of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> as treatment with Medroxyprogesterone Acetate Injectable Suspension, USP continues, without other therapy being required.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In the largest clinical trial with Medroxyprogesterone Acetate Injectable Suspension, USP, over 3,900 women, who were treated for up to 7 years, reported the following adverse reactions, which may or may not be related to the use of Medroxyprogesterone Acetate Injectable Suspension, USP.</p>
<p>The following adverse reactions were reported by more than 5% of subjects:</p>
<dl>
<dt>  </dt>
<dd>Menstrual irregularities (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, or both)</dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </dd>
<dt>  </dt>
<dd>Weight changes </dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> (<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>) </dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></dd>
</dl>
<p>Adverse reactions reported by 1% to 5% of subjects using Medroxyprogesterone Acetate Injectable Suspension, USP were: </p>
<dl>
<dt>  </dt>
<dd>Decreased libido or <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span> </dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span></dd>
<dt>  </dt>
<dd>No hair growth or <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> </dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
<dt>  </dt>
<dd><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></dd>
</dl>
<p>Events reported by fewer than 1% of subjects included: <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span>, <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, changes in appetite, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, genitourinary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4076012" conceptname="Cyst of vagina">vaginal cysts</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">body odor</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, changes in breast size, <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or nipple <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, axillary <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, breast cancer, prevention of lactation, sensation of pregnancy, lack of return to fertility, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial palsy</span>, <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, uterine <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, cervical cancer, <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, unexpected pregnancy, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">There have been rare cases of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> including <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span> reported postmarketing in patients taking Medroxyprogesterone Acetate Injectable Suspension, USP.  In addition, there have been voluntary reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> associated with the use of Medroxyprogesterone Acetate Injectable Suspension, USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_Administration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Both the 1 mL vial and the 1 mL prefilled syringe of Medroxyprogesterone Acetate Injectable Suspension, USP should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.</p>
<p>The recommended dose is 150 mg of Medroxyprogesterone Acetate Injectable Suspension, USP every 3 months (13 weeks) administered by deep, IM injection in the gluteal or deltoid muscle. To ensure the patient is not pregnant at the time of the first injection, the first injection <span class="Bold">MUST</span> be given <span class="Bold">ONLY</span> during the first 5 days of a normal menstrual period; <span class="Bold">ONLY</span> within the first 5-days postpartum if not breast-feeding; and if exclusively breast-feeding, <span class="Bold">ONLY</span> at the sixth postpartum week. If the time interval between injections is greater than 13 weeks, the physician should determine that the patient is not pregnant before administering the drug. The efficacy of depends on adherence to the dosage schedule of a Medroxyprogesterone Acetate Injectable Suspension, USP administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Medroxyprogesterone Acetate Injectable Suspension, USP (Medroxyprogesterone Acetate sterile aqueous suspension 150 mg/mL) is available as:</p>
<p>1 mL vial                                   NDC 54868-5257-0</p>
<p><br></p>
<p>Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Trussell J, Hatcher RA, Cates W Jr, Stewart FH, Kost K. A guide to interpreting contraceptive efficacy studies. <span class="Underline">Obstet</span> <span class="Underline">Gynecol.</span> 1990; <span class="Italics">76</span>:558–567.</li>
<li>Schwallie PC, Assenzo JR. Contraceptive use-efficacy study utilizing Medroxyprogesterone Acetate administered as an intramuscular injection once every 90 days. <span class="Underline">Fertil Steril</span>. 1973; <span class="Italics">24</span>:331–339.</li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multi-national study. <span class="Underline">Lancet</span>. 1991; <span class="Italics">338</span>:833–838.</li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-Medroxyprogesterone Acetate (DMPA) and risk of epithelial ovarian cancer. <span class="Underline">Int J Cancer.</span> 1991; <span class="Italics">49</span>:191–195.</li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-Medroxyprogesterone Acetate (DMPA) and risk of liver cancer. <span class="Underline">Int J Cancer</span>. 1991; <span class="Italics">49</span>:182185.</li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-Medroxyprogesterone Acetate (DMPA) and risk of invasive squamous-cell cervical cancer. <span class="Underline">Contraception</span>. 1992; <span class="Italics">45</span>:299–312.</li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-Medroxyprogesterone Acetate (DMPA) and risk of endometrial cancer. <span class="Underline">Int J Cancer</span>. 1991; <span class="Italics">49</span>:186–190.</li>
<li>Surveillance, Epidemiology, and End Results: Incidence and Mortality Data, 1973–1977. National Cancer Institute Monograph, 57: June 1981. (NIH publication No. 81-2330).</li>
<li>Gray RH, Pardthaisong T. <span class="Italics">In Utero</span> exposure to steroid contraceptives and survival during infancy. <span class="Underline">Am J Epidemiol</span>. 1991; <span class="Italics">134</span>:804–811.</li>
<li>Pardthaisong T, Gray RH. <span class="Italics">In Utero</span> exposure to steroid contraceptives and outcome of pregnancy. <span class="Underline">Am J Epidemiol</span>. 1991; <span class="Italics">134</span>:795–803.</li>
<li>Pardthaisong T, Gray RH, McDaniel EB, Chandacham A. Steroid contraceptive use and pregnancy outcome. <span class="Underline">Teratology</span>. 1988; <span class="Italics">38</span>:51–58.</li>
<li>Van Deijk WA, Biljham GH, Mellink WAM, Meulenberg PMM. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. <span class="Underline">Cancer Treatment Reports</span>. 1985; <span class="Italics">69</span>:1, 85–90.</li>
<li>Paul C, Skegg DCG, Spears GFS. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. <span class="Underline">Br Med J</span>. 1989; <span class="Italics">299</span>:759–762.</li>
<li>Skegg DCG, Noonan EA, Paul C, Spears GFS, Meirik O, Thomas DB. Depot Medroxyprogesterone Acetate and Breast Cancer: A Pooled Analysis from the World Health Organization and New Zealand Studies. <span class="Underline">JAMA</span>. 1995; <span class="Italics">273(10)</span>:799–804.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cd0bbdb2-754e-4e66-8f36-985b5819d642&amp;name=medroxyprogesterone-02.jpg"></p>
<p>LAB-0150-5.0<br>June 2008</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling of "Additional" barcode label by:</span></p>
<p>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Patient_Labeling"></a><a name="section-14"></a><p></p>
<h1>Medroxyprogesterone Acetate Injectable Suspension, USP</h1>
<p class="First"><span class="Bold">Patient Labeling</span></p>
<div class="Warning">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Use of Medroxyprogesterone Acetate Injectable Suspension, USP may cause you to lose calcium stored in your bones.  The longer you use Medroxyprogesterone Acetate Injectable Suspension, USP the more calcium you are likely to lose.  The calcium may not return completely once you stop using Medroxyprogesterone Acetate Injectable Suspension, USP. </span></p>
<p><span class="Bold">Loss of calcium may cause weak, porous bones (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) that could increase the risk that your bones might break, especially after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.  It is not known whether your risk of developing <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> may be greater if you are a teenager when you start to use Medroxyprogesterone Acetate Injectable Suspension, USP.</span></p>
<p><span class="Bold">You should use Medroxyprogesterone Acetate Injectable Suspension, USP long term (for example, more than two years) only if other methods of birth control are not right for you. (See "Risks of Using Medroxyprogesterone Acetate Injectable Suspension, USP")</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">This product is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Bold">Introduction</span></p>
<p>Every woman who considers using Medroxyprogesterone Acetate Injectable Suspension, USP needs to understand the benefits and risks of this form of birth control and to discuss them with her health-care provider. This leaflet is intended to give you much of the information you will need in order to decide if Medroxyprogesterone Acetate Injectable Suspension, USP is the right choice for you. Your health-care provider will help you to compare Medroxyprogesterone Acetate Injectable Suspension, USP with other contraceptive methods and will answer any questions you have after you have read this information.</p>
<p>Medroxyprogesterone Acetate Injectable Suspension, USP is given as an intramuscular injection (a shot) in the buttock or upper arm once every 3 months (13 weeks). Promptly at the end of the 3-month interval, you will need to return to your health-care provider for your next injection in order to continue your contraceptive protection.</p>
<p>Medroxyprogesterone Acetate Injectable Suspension, USP contains medroxyprogesterone acetate, a chemical similar to (but not the same as) the natural hormone progesterone that is produced by your ovaries during the second half of your menstrual cycle. Medroxyprogesterone Acetate Injectable Suspension, USP acts by preventing your egg cells from ripening. If an egg is not released from the ovaries during your menstrual cycle, it cannot become fertilized by sperm and result in pregnancy. Medroxyprogesterone Acetate Injectable Suspension, USP also causes changes in the lining of your uterus that make it less likely for pregnancy to occur.</p>
<p><span class="Bold">Effectiveness of Medroxyprogesterone Acetate Injectable Suspension, USP</span></p>
<p>To ensure that Medroxyprogesterone Acetate Injectable Suspension, USP is not administered inadvertently to a pregnant woman, the first injection must be given <span class="Bold">ONLY</span> during the first 5 days of a normal menstrual period; <span class="Bold">ONLY</span> within the first 5-days postpartum if not breast-feeding, and if exclusively breast-feeding, <span class="Bold">ONLY</span> at the sixth postpartum week (see <span class="Bold">Administration of Medroxyprogesterone Acetate Injectable Suspension, USP). </span>The efficacy of Medroxyprogesterone Acetate Injectable Suspension, USP depends on adherence to the recommended dosage schedule.</p>
<p>Medroxyprogesterone Acetate Injectable Suspension, USP is over 99% effective, making it one of the most reliable methods of birth control available. This means that the average annual pregnancy rate is less than one for every 100 women who use Medroxyprogesterone Acetate Injectable Suspension, USP. The effectiveness of most contraceptive methods depends, in part, on how reliably each woman uses the method. The effectiveness of Medroxyprogesterone Acetate Injectable Suspension, USP depends only on the patient returning every 3 months (13 weeks) for her next injection.</p>
<p>The following table shows the percent of women who become pregnant while using different kinds of contraceptive methods. It gives both the lowest expected rate of pregnancy (the rate expected in women who use each method exactly as it should be used) and the typical rate of pregnancy (which includes women who became pregnant because they forgot to use their birth control or because they did not follow the directions exactly).</p>
<a name="if3c9f755-4a5d-4e1b-8762-81fd18cf367a"></a><table width="80%">
<caption><span>Percent of Women Experiencing an Accidental Pregnancy in the First Year of Continuous Use</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead><tr class="First Last">
<th align="left">Method</th>
<th align="center">Lowest</th>
<th align="center">Typical</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">
<span class="Italics">Source:</span> Trussell et al; <span class="Underline">Obstet Gynecol</span> 1990;76:558–567. </td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>From Norplant<span class="Sup">®</span> package insert.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Medroxyprogesterone Acetate</td>
<td align="center">0.3</td>
<td align="center">0.3</td>
</tr>
<tr>
<td align="left">Implants (Norplant)</td>
<td align="center">0.2<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td align="center">0.2<a href="#footnote-5" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Female sterilization</td>
<td align="center">0.2</td>
<td align="center">0.4</td>
</tr>
<tr>
<td align="left">Male sterilization</td>
<td align="center">0.1</td>
<td align="center">0.15</td>
</tr>
<tr>
<td align="left">Oral contraceptives (pill)</td>
<td align="center">—</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Combined</td>
<td align="center">0.1</td>
<td align="center">—</td>
</tr>
<tr>
<td align="left">  Progestogen only</td>
<td align="center">0.5</td>
<td align="center">—</td>
</tr>
<tr>
<td align="left">IUD</td>
<td align="center">—</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Progestasert</td>
<td align="center">2</td>
<td align="center">—</td>
</tr>
<tr>
<td align="left">  Copper T 380A</td>
<td align="center">0.8</td>
<td align="center">—</td>
</tr>
<tr>
<td align="left">Condom (without spermicide)</td>
<td align="center">2</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">Diaphragm (with spermicide)</td>
<td align="center">6</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left">Cervical cap</td>
<td align="center">6</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left">Withdrawal</td>
<td align="center">4</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left">Periodic abstinence</td>
<td align="center">1–9</td>
<td align="center">20</td>
</tr>
<tr>
<td align="left">Spermicide alone</td>
<td align="center">3</td>
<td align="center">21</td>
</tr>
<tr>
<td align="left">Vaginal sponge</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td align="left">  used before childbirth</td>
<td align="center">6</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left">  used after childbirth</td>
<td align="center">9</td>
<td align="center">28</td>
</tr>
<tr class="Last">
<td align="left">No method</td>
<td align="center">85</td>
<td align="center">85</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Who Should Not Use Medroxyprogesterone Acetate Injectable Suspension, USP</span></p>
<p>Certain women should not use Medroxyprogesterone Acetate Injectable Suspension, USP. You should not use Medroxyprogesterone Acetate Injectable Suspension, USP if you have any of the following conditions:</p>
<ul>
<li>if you think you might be pregnant</li>
<li>if you have any <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> without a known reason</li>
<li>if you have had cancer of the breast</li>
<li>if you have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>if you have or have had blood clots (<span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>) in your legs</li>
<li>if you have problems with your liver or liver disease</li>
<li>if you are allergic to Medroxyprogesterone Acetate Injectable Suspension, USP (medroxyprogesterone acetate or any of its other ingredients)</li>
</ul>
<p><span class="Bold">Other Things to Consider Before Choosing Medroxyprogesterone Acetate Injectable Suspension, USP</span></p>
<p>Before your doctor prescribes Medroxyprogesterone Acetate Injectable Suspension, USP, you will have a physical examination. It is important to tell your doctor or health-care provider if you have any of the following:</p>
<ul>
<li>a family history of cancer of the breast</li>
<li>an abnormal mammogram (breast X-ray), <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast disease</span>, breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or lumps, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from your nipples</li>
<li>kidney disease</li>
<li>irregular or scanty menstrual periods</li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>if you are taking any prescription or over-the-counter medications</li>
</ul>
<p>This product is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</p>
<p><span class="Bold">Return of Fertility</span></p>
<p>Because Medroxyprogesterone Acetate Injectable Suspension, USP is a long-acting birth control method, it takes some time after your last injection for its effect to wear off. Based on the results from a large study done in the United States, of those women who stop using Medroxyprogesterone Acetate Injectable Suspension, USP in order to become pregnant, about half of those who become pregnant do so in about 10 months after their last injection; about two-thirds of those who become pregnant do so in about 12 months, about 83% of those who become pregnant do so in about 15 months, and about 93% of those who become pregnant do so in about 18 months after their last injection. The length of time you use Medroxyprogesterone Acetate Injectable Suspension, USP has no effect on how long it takes you to become pregnant after you stop using it.</p>
<p><span class="Bold">Risks of Using Medroxyprogesterone Acetate Injectable Suspension, USP </span></p>
<p><span class="Italics">1. Losing Calcium from Your Bones</span></p>
<p>Medroxyprogesterone Acetate Injectable Suspension, USP use may decrease the amount of calcium in your bones.  The longer you are on Medroxyprogesterone Acetate Injectable Suspension, USP the more calcium you may lose.  This increases the risk of your bones weakening if you use Medroxyprogesterone Acetate Injectable Suspension, USP continuously for a long time (for more than 2 years).  The loss of calcium may increase your risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and broken bones, particularly after your <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
<p>Calcium is generally added to the bones during teenage years.  The decrease of calcium in your bones is of most concern if you are a teenager or have the following risk factors:</p>
<dl>
<dt>-</dt>
<dd>bone disease</dd>
<dt>-</dt>
<dd><span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span> (an eating disorder)</dd>
<dt>-</dt>
<dd>a strong family history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span></dd>
<dt>-</dt>
<dd>drug use that can lower the amount of calcium in bones (drugs for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or steroids), or</dd>
<dt>-</dt>
<dd>drinking a lot of alcohol or smoking a lot.</dd>
</dl>
<p>If you need a birth control method for more than 2 years, your healthcare provider may ask you to switch to another birth control method or ask you to have a test of your bones before continuing Medroxyprogesterone Acetate Injectable Suspension, USP, especially if you have other risks for weak bones.  When Medroxyprogesterone Acetate Injectable Suspension, USP is stopped, the calcium in bones begins to come back.  Your healthcare provider may tell you take calcium and Vitamin D as this may lessen the loss of calcium from your bones. </p>
<p><span class="Italics">2. Irregular Menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p>The side effect reported most frequently by women who use Medroxyprogesterone Acetate Injectable Suspension, USP for contraception is a change in their normal menstrual cycle. During the first year of using Medroxyprogesterone Acetate Injectable Suspension, USP, you might have one or more of the following changes:</p>
<ul>
<li>irregular or unpredictable <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting,</li>
<li>an increase or decrease in menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or</li>
<li>no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at all.</li>
</ul>
<p>Unusually heavy or continuous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, however, is not a usual effect of Medroxyprogesterone Acetate Injectable Suspension, USP and if this happens you should see your health-care provider right away.</p>
<p>With continued use of Medroxyprogesterone Acetate Injectable Suspension, USP, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> usually decreases and many women stop having periods completely. In clinical studies of Medroxyprogesterone Acetate Injectable Suspension, USP, 55% of the women studied reported no menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>) after 1 year of use and 68% of the women studied reported no menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> after 2 years of use.</p>
<p>The reason that your periods stop is because Medroxyprogesterone Acetate Injectable Suspension, USP causes a resting state in your ovaries. When your ovaries do not release an egg monthly, the regular monthly growth of the lining of your uterus does not occur and, therefore, the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that comes with your normal menstruation does not take place. When you stop using Medroxyprogesterone Acetate Injectable Suspension, USP your menstrual period will usually, in time, return to its normal cycle. </p>
<p><span class="Italics">3. Cancer</span></p>
<p>Studies of women who have used different forms of contraception found that women who used Medroxyprogesterone Acetate Injectable Suspension, USP for contraception had no increased overall risk of developing cancer of the breast, ovary, uterus, cervix, or liver. However, women under 35 years of age whose first exposure to Medroxyprogesterone Acetate Injectable Suspension, USP was within the previous 4 to 5 years may have a slightly increased risk of developing breast cancer similar to that seen with oral contraceptives. You should discuss this with your health-care provider. </p>
<p><span class="Italics">4. Unexpected Pregnancy</span></p>
<p>Because Medroxyprogesterone Acetate Injectable Suspension, USP is such an effective contraceptive method, the risk of unexpected pregnancy for women who get their shots regularly (every 3 months [13 weeks] ) is very low. While there have been reports of an increased risk of low birth weight and neonatal infant <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or other health problems in infants conceived close to the time of injection, such pregnancies are uncommon. If you think you may have become pregnant while using Medroxyprogesterone Acetate Injectable Suspension, USP for contraception, see your health-care provider as soon as possible. </p>
<p><span class="Italics">5. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> known as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have also been reported in some women using Medroxyprogesterone Acetate Injectable Suspension, USP. </p>
<p><span class="Italics">6. Other Risks</span></p>
<p>Women who use hormone-based contraceptives may have an increased risk of blood clots or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Also, if a contraceptive method fails, there is a possibility that the fertilized egg will begin to develop outside of the uterus (<span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>). While these events are rare, you should tell your health-care provider if you have any of the Warning Signals listed in the next section.</p>
<p><span class="Bold">Warning Signals</span></p>
<p>If any of these problems occur following an injection of Medroxyprogesterone Acetate Injectable Suspension, USP, call your healthcare provider immediately:</p>
<ul>
<li>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (indicating a possible clot in the lung)</li>
<li>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, problems with your eyesight or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the calf (indicating a possible clot in the leg)</li>
<li>Unusually heavy <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the lower abdominal area</li>
<li>Persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pus, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at the injection site </li>
</ul>
<p><span class="Bold">Side Effects of Medroxyprogesterone Acetate Injectable Suspension, USP</span></p>
<p><span class="Italics">1. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p>You may experience a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> while you are using Medroxyprogesterone Acetate Injectable Suspension, USP. About two-thirds of the women who used Medroxyprogesterone Acetate Injectable Suspension, USP in the clinical trials reported a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of about 5 pounds during the first year of use. You may continue to gain weight after the first year. Women in one large study who used Medroxyprogesterone Acetate Injectable Suspension, USP for 2 years gained an average total of 8.1 pounds over those 2 years, or approximately 4 pounds per year. Women who continued for 4 years gained an average total of 13.8 pounds over those 4 years, or approximately 3.5 pounds per year. Women who continued for 6 years gained an average total of 16.5 pounds over those 6 years, or approximately 2.75 pounds per year.</p>
<p><span class="Italics">2. Other Side Effects</span></p>
<p>In a clinical study of over 3,900 women who used Medroxyprogesterone Acetate Injectable Suspension, USP for up to 7 years, some women reported the following effects that may or may not have been related to their use of Medroxyprogesterone Acetate Injectable Suspension, USP:</p>
<a name="ib88ade75-4e14-4c31-8288-d24437baab23"></a><table width="80%">
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">•	irregular menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands or feet</td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span></td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> </td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> </td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </td>
<td align="left">•	no hair growth or excessive <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span></td>
</tr>
<tr>
<td align="left">•	decreased sexual desire</td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span></td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> or irritation</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">•	<span class="product-label-link" type="condition" conceptid="4114004" conceptname="Swelling of breast">breast swelling</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span></td>
<td align="left"></td>
</tr>
<tr class="Last">
<td align="left">•	<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>Other problems were reported by very few of the women in the clinical trials, but some of these could be serious. These include: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, lack of return to fertility, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, breast cancer, or cervical cancer. If these or any other problems occur during your use of Medroxyprogesterone Acetate Injectable Suspension, USP, discuss them with your health-care provider.</p>
<p><span class="Bold">General Precautions</span></p>
<p><span class="Italics">1. Missed Periods</span></p>
<p>During the time you are using Medroxyprogesterone Acetate Injectable Suspension, USP for contraception, you may skip a period, or your periods may stop completely. If you have been receiving your injection of Medroxyprogesterone Acetate Injectable Suspension, USP regularly every 3 months (13 weeks), then you are probably not pregnant. However, if you think that you may be pregnant, see your health-care provider. </p>
<p><span class="Italics">2. Laboratory Test Interactions </span></p>
<p>If you are scheduled for any laboratory tests, tell your health-care provider that you are using Medroxyprogesterone Acetate Injectable Suspension, USP for contraception. Certain blood tests are affected by hormones such as Medroxyprogesterone Acetate Injectable Suspension, USP.</p>
<p><span class="Italics">3. Drug Interactions</span></p>
<p>Cytadren (aminoglutethimide) is an anticancer drug that may significantly decrease the effectiveness of Medroxyprogesterone Acetate Injectable Suspension, USP if the two drugs are given during the same time.</p>
<p><span class="Italics">4. Nursing Mothers</span></p>
<p>Although Medroxyprogesterone Acetate Injectable Suspension, USP can be passed to the nursing infant in the breast milk, no harmful effects have been found in these children. Medroxyprogesterone Acetate Injectable Suspension, USP does not prevent the breasts from producing milk, so it can be used by nursing mothers. However, to minimize the amount of Medroxyprogesterone Acetate Injectable Suspension, USP that is passed to the infant in the first weeks after birth, you should wait until 6 weeks after childbirth before you start using Medroxyprogesterone Acetate Injectable Suspension, USP for contraception.</p>
<p><span class="Bold">Administration of Medroxyprogesterone Acetate Injectable Suspension, USP</span></p>
<p>The recommended dose of Medroxyprogesterone Acetate Injectable Suspension, USP is 150 mg every 3 months (13 weeks) given in a single intramuscular injection in the buttock or upper arm. To ensure that you are not pregnant at the time of the first injection, it is essential that the injection be given <span class="Bold">ONLY</span> during the first 5 days of a normal menstrual period. If used following the delivery of a child, the first injection of Medroxyprogesterone Acetate Injectable Suspension, USP <span class="Bold">MUST</span> be given within 5 days after childbirth if you are not breast-feeding, or if you are exclusively breast-feeding, the injection <span class="Bold">MUST</span> be given 6 weeks after childbirth. If you wait longer than 3 months (13 weeks) between injections, or longer than 6 weeks after delivery, your health-care provider should determine that you are not pregnant before giving you your injection of Medroxyprogesterone Acetate Injectable Suspension, USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cd0bbdb2-754e-4e66-8f36-985b5819d642&amp;name=medroxyprogesterone-02.jpg"></p>
<p>LAB-0152-5.0<br>June 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL Vial</h1>
<p class="First"><span class="Bold">NDC</span> 54868-5257-0</p>
<p><img alt="image of 150 mg/1 mL package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cd0bbdb2-754e-4e66-8f36-985b5819d642&amp;name=5257.jpg"></p>
<p><span class="Bold">medroxyprogesterone<br>acetate injectable<br>suspension, USP</span></p>
<p><span class="Bold">150 mg in 1 mL</span></p>
<p>Intramuscular Use Only</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEDROXYPROGESTERONE ACETATE 		
					</strong><br><span class="contentTableReg">medroxyprogesterone acetate injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5257(NDC:59762-4537)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEDROXYPROGESTERONE ACETATE</strong> (MEDROXYPROGESTERONE) </td>
<td class="formItem">MEDROXYPROGESTERONE</td>
<td class="formItem">150 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">28.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">2.41 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.68 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">1.37 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">0.15 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5257-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020246</td>
<td class="formItem">03/31/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e55e0e7-d2d6-40f2-8d84-66cf9768c737</div>
<div>Set id: cd0bbdb2-754e-4e66-8f36-985b5819d642</div>
<div>Version: 1</div>
<div>Effective Time: 20090813</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
